Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

A stromal cell niche sustains ILC2-mediated type-2 conditioning in adipose tissue.

Rana BMJ, Jou E, Barlow JL, Rodriguez-Rodriguez N, Walker JA, Knox C, Jolin HE, Hardman CS, Sivasubramaniam M, Szeto A, Cohen ES, Scott IC, Sleeman MA, Chidomere CI, Cruz Migoni S, Caamano J, Jorgensen HF, Carobbio S, Vidal-Puig A, McKenzie ANJ.

J Exp Med. 2019 Jun 27. pii: jem.20190689. doi: 10.1084/jem.20190689. [Epub ahead of print]

PMID:
31248899
2.

Peripheral lymph nodes contain migratory and resident innate lymphoid cell populations.

Dutton EE, Gajdasik DW, Willis C, Fiancette R, Bishop EL, Camelo A, Sleeman MA, Coccia M, Didierlaurent AM, Tomura M, Pilataxi F, Morehouse CA, Carlesso G, Withers DR.

Sci Immunol. 2019 May 31;4(35). pii: eaau8082. doi: 10.1126/sciimmunol.aau8082.

PMID:
31152090
3.

Neutrophil GM-CSF receptor dynamics in acute lung injury.

De Alessandris S, Ferguson GJ, Dodd AJ, Juss JK, Devaprasad A, Piper S, Wyatt O, Killick H, Corkill DJ, Cohen ES, Pandit A, Radstake TRDJ, Simmonds R, Condliffe AM, Sleeman MA, Cowburn AS, Finch DK, Chilvers ER.

J Leukoc Biol. 2019 Jun;105(6):1183-1194. doi: 10.1002/JLB.3MA0918-347R. Epub 2019 Apr 3.

4.

Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.

Vousden KA, Lundqvist T, Popovic B, Naiman B, Carruthers AM, Newton P, Johnson DJD, Pomowski A, Wilkinson T, Dufner P, de Mendez I, Mallinder PR, Murray C, Strain M, Connor J, Murray LA, Sleeman MA, Lowe DC, Huntington JA, Vaughan TJ.

Sci Rep. 2019 Feb 7;9(1):1605. doi: 10.1038/s41598-019-38842-x.

5.

Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype.

Wang B, Zhang W, Jankovic V, Golubov J, Poon P, Oswald EM, Gurer C, Wei J, Ramos I, Wu Q, Waite J, Ni M, Adler C, Wei Y, Macdonald L, Rowlands T, Brydges S, Siao J, Poueymirou W, MacDonald D, Yancopoulos GD, Sleeman MA, Murphy AJ, Skokos D.

Sci Immunol. 2018 Nov 2;3(29). pii: eaat7061. doi: 10.1126/sciimmunol.aat7061.

PMID:
30389797
6.

Identification of periplakin as a major regulator of lung injury and repair in mice.

Besnard V, Dagher R, Madjer T, Joannes A, Jaillet M, Kolb M, Bonniaud P, Murray LA, Sleeman MA, Crestani B.

JCI Insight. 2018 Mar 8;3(5). pii: 90163. doi: 10.1172/jci.insight.90163.

7.

Serum biomarker profiles suggest that atopic dermatitis is a systemic disease.

Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, Nierkens S, Giovannone B, Knol EF, Csomor E, Sellman BR, Mustelin T, Sleeman MA, de Bruin-Weller MS, Herath A, Drylewicz J, May RD, Hijnen D.

J Allergy Clin Immunol. 2018 Apr;141(4):1523-1526. doi: 10.1016/j.jaci.2017.12.991. Epub 2018 Feb 2. No abstract available.

PMID:
29410314
8.

Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.6.

PMID:
29362468
9.

Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain.

Nicol LSC, Thornton P, Hatcher JP, Glover CP, Webster CI, Burrell M, Hammett K, Jones CA, Sleeman MA, Billinton A, Chessell I.

Pain. 2018 Mar;159(3):550-559. doi: 10.1097/j.pain.0000000000001130.

10.

IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells.

Camelo A, Rosignoli G, Ohne Y, Stewart RA, Overed-Sayer C, Sleeman MA, May RD.

Blood Adv. 2017 Mar 30;1(10):577-589. doi: 10.1182/bloodadvances.2016002352. eCollection 2017 Apr 11.

11.

The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

12.

IL-18 associated with lung lymphoid aggregates drives IFNγ production in severe COPD.

Briend E, Ferguson GJ, Mori M, Damera G, Stephenson K, Karp NA, Sethi S, Ward CK, Sleeman MA, Erjefält JS, Finch DK.

Respir Res. 2017 Aug 22;18(1):159. doi: 10.1186/s12931-017-0641-7.

13.

EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients.

Thijs JL, Drylewicz J, Fiechter R, Strickland I, Sleeman MA, Herath A, May RD, Bruijnzeel-Koomen CAFM, Knol EF, Giovannone B, de Bruin-Weller MS, Nierkens S, Hijnen DJ.

J Allergy Clin Immunol. 2017 Dec;140(6):1703-1705. doi: 10.1016/j.jaci.2017.06.046. Epub 2017 Aug 16. No abstract available.

PMID:
28823810
14.

Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis.

Murray LA, Habiel DM, Hohmann M, Camelo A, Shang H, Zhou Y, Coelho AL, Peng X, Gulati M, Crestani B, Sleeman MA, Mustelin T, Moore MW, Ryu C, Osafo-Addo AD, Elias JA, Lee CG, Hu B, Herazo-Maya JD, Knight DA, Hogaboam CM, Herzog EL.

JCI Insight. 2017 Aug 17;2(16). pii: 92192. doi: 10.1172/jci.insight.92192. eCollection 2017 Aug 17.

15.

Targeting the GM-CSF receptor for the treatment of CNS autoimmunity.

Ifergan I, Davidson TS, Kebir H, Xu D, Palacios-Macapagal D, Cann J, Rodgers JM, Hunter ZN, Pittet CL, Beddow S, Jones CA, Prat A, Sleeman MA, Miller SD.

J Autoimmun. 2017 Nov;84:1-11. doi: 10.1016/j.jaut.2017.06.005. Epub 2017 Jun 20.

16.

Acute cigarette smoke exposure activates apoptotic and inflammatory programs but a second stimulus is required to induce epithelial to mesenchymal transition in COPD epithelium.

Murray LA, Dunmore R, Camelo A, Da Silva CA, Gustavsson MJ, Habiel DM, Hackett TL, Hogaboam CM, Sleeman MA, Knight DA.

Respir Res. 2017 May 3;18(1):82. doi: 10.1186/s12931-017-0565-2.

17.

Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.

Thijs JL, Strickland I, Bruijnzeel-Koomen CAFM, Nierkens S, Giovannone B, Csomor E, Sellman BR, Mustelin T, Sleeman MA, de Bruin-Weller MS, Herath A, Drylewicz J, May RD, Hijnen D.

J Allergy Clin Immunol. 2017 Sep;140(3):730-737. doi: 10.1016/j.jaci.2017.03.023. Epub 2017 Apr 13. Erratum in: J Allergy Clin Immunol. 2018 Aug;142(2):714.

PMID:
28412391
18.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

19.

Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation.

Cook AD, Louis C, Robinson MJ, Saleh R, Sleeman MA, Hamilton JA.

Arthritis Res Ther. 2016 Dec 1;18(1):287.

20.

The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies.

Hepburn L, Hijnen DJ, Sellman BR, Mustelin T, Sleeman MA, May RD, Strickland I.

Br J Dermatol. 2017 Jul;177(1):63-71. doi: 10.1111/bjd.15139. Epub 2017 Jun 11. Review.

PMID:
27779765
21.

Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?

Clarke DL, Murray LA, Crestani B, Sleeman MA.

Pharmacol Ther. 2017 Jan;169:35-46. doi: 10.1016/j.pharmthera.2016.09.010. Review.

PMID:
27612548
22.

GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease.

Stock AT, Hansen JA, Sleeman MA, McKenzie BS, Wicks IP.

J Exp Med. 2016 Sep 19;213(10):1983-98. doi: 10.1084/jem.20151853. Epub 2016 Sep 5.

23.

Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.

Campbell J, Nys J, Eghobamien L, Cohen ES, Robinson MJ, Sleeman MA.

MAbs. 2016 Oct;8(7):1398-1406. Epub 2016 Aug 12.

24.

Living with Fibrosis: From Diagnosis to Future Hope.

Sleeman MA, Parker J, Murray LA.

Front Pharmacol. 2015 Dec 16;6:288. doi: 10.3389/fphar.2015.00288. eCollection 2015. No abstract available.

25.

Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation.

Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, Rees DG, Overed-Sayer CL, Woods J, Bond NJ, Veyssier CS, Embrey KJ, Sims DA, Snaith MR, Vousden KA, Strain MD, Chan DT, Carmen S, Huntington CE, Flavell L, Xu J, Popovic B, Brightling CE, Vaughan TJ, Butler R, Lowe DC, Higazi DR, Corkill DJ, May RD, Sleeman MA, Mustelin T.

Nat Commun. 2015 Sep 14;6:8327. doi: 10.1038/ncomms9327.

26.

Thematic Issue: Rheumatology: An Evolutionary force in Biologics.

Sleeman MA.

Curr Pharm Des. 2015;21(17):2168-9. No abstract available.

PMID:
25771252
27.

Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals.

Vainshtein I, Roskos LK, Cheng J, Sleeman MA, Wang B, Liang M.

Pharm Res. 2015 Jan;32(1):286-99. doi: 10.1007/s11095-014-1462-8. Epub 2014 Sep 11.

28.

Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.

Ryan PC, Sleeman MA, Rebelatto M, Wang B, Lu H, Chen X, Wu CY, Hinrichs MJ, Roskos L, Towers H, McKeever K, Dixit R.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):230-9. doi: 10.1016/j.taap.2014.06.002. Epub 2014 Jun 15.

29.

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.

Greven DE, Cohen ES, Gerlag DM, Campbell J, Woods J, Davis N, van Nieuwenhuijze A, Lewis A, Heasmen S, McCourt M, Corkill D, Dodd A, Elvin J, Statache G, Wicks IP, Anderson IK, Nash A, Sleeman MA, Tak PP.

Ann Rheum Dis. 2015 Oct;74(10):1924-30. doi: 10.1136/annrheumdis-2014-205234. Epub 2014 Jun 16.

30.

Danger-associated molecular patterns and danger signals in idiopathic pulmonary fibrosis.

Ellson CD, Dunmore R, Hogaboam CM, Sleeman MA, Murray LA.

Am J Respir Cell Mol Biol. 2014 Aug;51(2):163-8. doi: 10.1165/rcmb.2013-0366TR. Review.

PMID:
24749648
31.

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.

Camelo A, Dunmore R, Sleeman MA, Clarke DL.

Front Pharmacol. 2014 Jan 10;4:173. doi: 10.3389/fphar.2013.00173. eCollection 2014 Jan 10. Review.

32.

Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Murray LA, Zhang H, Oak SR, Coelho AL, Herath A, Flaherty KR, Lee J, Bell M, Knight DA, Martinez FJ, Sleeman MA, Herzog EL, Hogaboam CM.

Am J Respir Cell Mol Biol. 2014 May;50(5):985-94. doi: 10.1165/rcmb.2013-0342OC.

33.

Development of a mouse model mimicking key aspects of a viral asthma exacerbation.

Clarke DL, Davis NH, Majithiya JB, Piper SC, Lewis A, Sleeman MA, Corkill DJ, May RD.

Clin Sci (Lond). 2014 Apr;126(8):567-80. doi: 10.1042/CS20130149.

PMID:
24152048
34.

Dectin-2 sensing of house dust mite is critical for the initiation of airway inflammation.

Clarke DL, Davis NH, Campion CL, Foster ML, Heasman SC, Lewis AR, Anderson IK, Corkill DJ, Sleeman MA, May RD, Robinson MJ.

Mucosal Immunol. 2014 May;7(3):558-67. doi: 10.1038/mi.2013.74. Epub 2013 Oct 16.

35.

An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation.

Traub S, Nikonova A, Carruthers A, Dunmore R, Vousden KA, Gogsadze L, Hao W, Zhu Q, Bernard K, Zhu J, Dymond M, McLean GR, Walton RP, Glanville N, Humbles A, Khaitov M, Wells T, Kolbeck R, Leishman AJ, Sleeman MA, Bartlett NW, Johnston SL.

PLoS Pathog. 2013;9(8):e1003520. doi: 10.1371/journal.ppat.1003520. Epub 2013 Aug 1.

36.

GM-CSF as a therapeutic target in inflammatory diseases.

van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, Wicks IP.

Mol Immunol. 2013 Dec;56(4):675-82. doi: 10.1016/j.molimm.2013.05.002. Epub 2013 Aug 8. Review.

PMID:
23933508
37.

The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells.

Piper SC, Ferguson J, Kay L, Parker LC, Sabroe I, Sleeman MA, Briend E, Finch DK.

PLoS One. 2013 May 28;8(5):e63365. doi: 10.1371/journal.pone.0063365. Print 2013.

38.

Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity.

Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, Sleeman MA, Davis DM.

Blood. 2013 Jun 6;121(23):4694-702. doi: 10.1182/blood-2013-02-482570. Epub 2013 Apr 23.

39.

Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease.

Finch DK, Ettinger R, Karnell JL, Herbst R, Sleeman MA.

Eur J Clin Invest. 2013 May;43(5):501-9. doi: 10.1111/eci.12063. Epub 2013 Mar 20. Review.

PMID:
23517338
40.

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.

Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F; EARTH Study Group.

Ann Rheum Dis. 2013 Sep 1;72(9):1445-52. doi: 10.1136/annrheumdis-2012-202450. Epub 2012 Dec 12.

41.

Development of a homogeneous high-throughput screening assay for biological inhibitors of human rhinovirus infection.

Newton P, O'Shea D, Wells E, Moakes K, Dunmore R, Butler RJ, Wilkinson T, Ward A, Casson N, Strain M, Vousden K, Lowe DC, Pattison DV, Carruthers AM, Sleeman MA, Vaughan TJ, Harrison P.

J Biomol Screen. 2013 Mar;18(3):237-46. doi: 10.1177/1087057112469047. Epub 2012 Dec 3.

PMID:
23207740
42.

Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis.

Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, Eghobamien L, Harrison P, Sims DA, Matthews C, Wilkinson T, Monk P, Drinkwater C, Fabri L, Nash A, McCourt M, Jermutus L, Roskos L, Anderson IK, Sleeman MA.

Br J Pharmacol. 2013 Jan;168(1):200-11. doi: 10.1111/j.1476-5381.2012.02173.x.

43.

Angiopoietin-2 promotes inflammatory activation of human macrophages and is essential for murine experimental arthritis.

Krausz S, Garcia S, Ambarus CA, de Launay D, Foster M, Naiman B, Iverson W, Connor JR, Sleeman MA, Coyle AJ, Hamann J, Baeten D, Tak PP, Reedquist KA.

Ann Rheum Dis. 2012 Aug;71(8):1402-10. doi: 10.1136/annrheumdis-2011-200718. Epub 2012 Jun 22.

PMID:
22730375
44.

Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics.

Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S, Rendall E, Sinha M, Walker C, Rees G, Bowen MA, Schneider A, Liang M, Faggioni R, Fung M, Mallinder PR, Wilkinson T, Kolbeck R, Vaughan T, Lowe DC.

J Mol Biol. 2011 Aug 26;411(4):791-807. doi: 10.1016/j.jmb.2011.06.031. Epub 2011 Jun 23.

PMID:
21723291
45.

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.

Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F.

Ann Rheum Dis. 2011 Sep;70(9):1542-9. doi: 10.1136/ard.2010.146225. Epub 2011 May 25.

46.

A mouse GM-CSF receptor antibody attenuates neutrophilia in mice exposed to cigarette smoke.

Botelho FM, Nikota JK, Bauer C, Davis NH, Cohen ES, Anderson IK, Coyle AJ, Kolbeck R, Humbles AA, Stämpfli MR, Sleeman MA.

Eur Respir J. 2011 Aug;38(2):285-94. doi: 10.1183/09031936.00076210. Epub 2011 Mar 24.

47.

Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Campbell J, Lowe D, Sleeman MA.

Br J Pharmacol. 2011 Apr;162(7):1470-84. doi: 10.1111/j.1476-5381.2010.01183.x. Review.

48.

Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.

Finch DK, Midha A, Buchanan CL, Cochrane D, Craggs RI, Cruwys S, Grahames C, Kolbeck R, Lowe DC, Maltby J, Pattison DV, Vousden KA, Ward A, Sleeman MA, Mallinder PR.

Br J Pharmacol. 2011 Jan;162(2):480-90. doi: 10.1111/j.1476-5381.2010.01061.x.

49.

Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD.

Doe C, Bafadhel M, Siddiqui S, Desai D, Mistry V, Rugman P, McCormick M, Woods J, May R, Sleeman MA, Anderson IK, Brightling CE.

Chest. 2010 Nov;138(5):1140-7. doi: 10.1378/chest.09-3058. Epub 2010 Jun 10.

50.

TGFbeta/Smad4-dependent and -independent regulation of human lens epithelial cells.

Dawes LJ, Sleeman MA, Anderson IK, Reddan JR, Wormstone IM.

Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5318-27. doi: 10.1167/iovs.08-3223. Epub 2009 Jun 10.

PMID:
19516008

Supplemental Content

Loading ...
Support Center